Congratulations to our partner, Akeso Inc., who announced groundbreaking results of their Phase III clinical study (HARMONi-2/AK112-303) with its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in The Lancet. The Lancet is a prestigious international medical journal. You can view the publication here: https://lnkd.in/gAXsDUeX. #SMMTNewEra #SummitTherapeutics #ivonescimab #thelancet Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).